improving treatment and sharing decision making in pancreatic cancer

Improving Treatment and Sharing Decision Making in

Pancreatic Cancer

Activity Goals

Pancreatic Cancer: Incidence/Survival

Cellular Classification of Pancreatic Cancer

Biology of Pancreatic Cancer

Diagnosis and Staging

Endoscopic Ultrasound-guided FNA of a Pancreatic Mass Lesion

Sites of Pancreatic Neoplasia Not Seen by Triple-phase CT

To Determine When Obstructive Jaundice Is Associated With Pancreatic Cancer

Resectable Tumor

Management of Obstructive Jaundice

Placement of Biliary Stent

Neoadjuvant Trials on Borderline Resectable Pancreatic Cancer

CA19-9: Its Role in Pancreatic Cancer

Role of Laparoscopy in Pancreatic Cancer

Role of Neoadjuvant Therapy (NAT)

NAT for Resectable and Borderline-resectable Pancreatic Cancer

Multidisciplinary and Experienced Approach

An Overview of Gemcitabine-based Therapies

Agents for Metastatic Pancreatic Cancer

ACCORD Study: FOLFIRINOX vs Gemcitabine

ACCORD Study: Baseline Characteristics

ACCORD Study: Safety

Improved OS With FOLFIRINOX

ACCORD Study: Efficacy

Nab-Paclitaxel vs Gemcitabine: Study Design

Efficacy of Nab-Paclitaxel vs Gemcitabine

Palliative Care

Paucity of Enrollment in Clinical Trials

Clinical Trials Open in the US in 2011 and 2012 by Disease

Stage

Educate Patients Early About Enrollment in Clinical Trials

Patient Example

Patient Education

Phase 2 Study of MM-398

Combinations in Clinical Trials

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)